Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Archives of Psychiatry and Clinical Neuroscience
Published in: European Archives of Psychiatry and Clinical Neuroscience 7/2021

Open Access 01-10-2021 | Antiepileptic Drugs | Original Paper

Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs

Authors: T. Hebel, M. A. Abdelnaim, M. Deppe, P. M. Kreuzer, A. Mohonko, T. B. Poeppl, R. Rupprecht, B. Langguth, M. Schecklmann

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2021

Login to get access

Abstract

Introduction

The effect of concomitant medication on repetitive transcranial magnetic stimulation (rTMS) outcomes in depression remains understudied. Recent analyses show attenuation of rTMS effects by antipsychotic medication and benzodiazepines, but data on the effects of antiepileptic drugs and lithium used as mood stabilizers or augmenting agents are sparse despite clinical relevance. Preclinical electrophysiological studies suggest relevant impact of the medication on treatment, but this might not translate into clinical practice. We aimed to investigate the role of lithium (Li), lamotrigine (LTG) and valproic acid (VPA) by analyzing rTMS treatment outcomes in depressed patients.

Methods

299 patients with uni- and bipolar depression treated with rTMS were selected for analysis in respect to intake of lithium, lamotrigine and valproic acid. The majority (n = 251) were treated with high-frequency (10–20 Hz) rTMS of the lDLPFC for an average of 17 treatment sessions with a figure-of-8 coil with a MagVenture system aiming for 110% resting motor threshold, and smaller groups of patients were being treated with other protocols including intermittent theta-burst stimulation and bilateral prefrontal and medial prefrontal protocols. For group comparisons, we used analysis of variance with the between-subjects factor group or Chi-Square Test of Independence depending on the scales of measurement. For post-hoc tests, we used least significant difference (LSD). For differences in treatment effects between groups, we used an ANOVA with the between-subjects factor group (groups: no mood stabilizer, Li, LTG, VPA, Li + LTG) the within-subjects factor treatment (pre vs. post treatment with rTMS) and also Chi-Square Tests of independence for response and remission.

Results

Overall, patients showed an amelioration of symptoms with no significant differences for the main effect of group and for the interaction effect treatment by group. Based on direct comparisons between the single groups taking mood stabilizers against the group taking no mood stabilizers, we see a superior effect of lamotrigine, valproic acid and combination of lithium and lamotrigine for the response and remission rates. Motor threshold was significantly and markedly higher for patients taking valproic acid.

Conclusion

Being treated with lithium, lamotrigine and valproic acid had no relevant influence on rTMS treatment outcome. The results suggest there is no reason for clinicians to withhold or withdraw these types of medication from patients who are about to undergo a course of rTMS. Prospective controlled work on the subject is encouraged.
Literature
1.
Bialer M (2012) Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53(Suppl 7):26–33CrossRef
2.
Cantello R, Civardi C, Varrasi C, Vicentini R, Cecchin M, Boccagni C, Monaco F (2006) Excitability of the human epileptic cortex after chronic valproate: a reappraisal. Brain Res 1099:160–166CrossRef
3.
Charlotte M, Schwartz E, Slade E, Medoff D, Li L, Dixon L, Kilbourne AM, Kreyenbuhl J (2015) Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness. J Affect Disord 188:112–117CrossRef
4.
Delvendahl I, Lindemann H, Heidegger T, Normann C, Ziemann U, Mall V (2013) Effects of lamotrigine on human motor cortex plasticity. Clin Neurophysiol 124:148–153CrossRef
5.
Deppe M, Abdelnaim M, Hebel T, Kreuzer PM, Poeppl TB, Langguth B, Schecklmann M (2020) Concomitant lorazepam use and antidepressive efficacy of repetitive transcranial magnetic stimulation in a naturalistic setting. Eur Arch Psychiatry Clin Neurosci 271:61–67CrossRef
6.
Ferrarelli F, Massimini M, Sarasso S, Casali A, Riedner BA, Angelini G, Tononi G, Pearce RA (2010) Breakdown in cortical effective connectivity during midazolam-induced loss of consciousness. Proc Natl Acad Sci USA 107:2681–2686CrossRef
7.
Fitzgerald PB, Daskalakis ZJ, Hoy KE (2020) Benzodiazepine use and response to repetitive transcranial magnetic stimulation in Major Depressive Disorder. Brain Stimul 13:694–695CrossRef
8.
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA (2010) Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 67:507–516CrossRef
9.
Ghabrash MF, Comai S, Tabaka J, Saint-Laurent M, Booij L, Gobbi G (2016) Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression. World J Biol Psychiatry 17:165–170CrossRef
10.
Goh KK, Chen CH, Chiu YH, Lu ML (2019) Lamotrigine augmentation in treatment-resistant unipolar depression: a comprehensive meta-analysis of efficacy and safety. J Psychopharmacol 33:700–713CrossRef
11.
Hantouche EG, Akiskal HS, Lancrenon S, Chatenet-Duchene L (2005) Mood stabilizer augmentation in apparently “unipolar” MDD: predictors of response in the naturalistic French national EPIDEP study. J Affect Disord 84:243–249CrossRef
12.
Hebel T, Abdelnaim M, Deppe M, Langguth B, Schecklmann M (2020) Attenuation of antidepressive effects of transcranial magnetic stimulation in patients whose medication includes drugs for psychosis. J Psychopharmacol, 269881120922965
13.
Heidegger T, Krakow K, Ziemann U (2010) Effects of antiepileptic drugs on associative LTP-like plasticity in human motor cortex. Eur J Neurosci 32:1215–1222CrossRef
14.
Hubers A, Voytovych H, Heidegger T, Muller-Dahlhaus F, Ziemann U (2014) Acute effects of lithium on excitability of human motor cortex. Clin Neurophysiol 125:2240–2246CrossRef
15.
Hunter AM, Minzenberg MJ, Cook IA, Krantz DE, Levitt JG, Rotstein NM, Chawla SA, Leuchter AF (2019) Concomitant medication use and clinical outcome of repetitive Transcranial Magnetic Stimulation (rTMS) treatment of Major Depressive Disorder. Brain Behav 9:e01275CrossRef
16.
Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Hillsdale, NJ
17.
Karanti A, Bobeck C, Osterman M, Kardell M, Tidemalm D, Runeson B, Lichtenstein P, Landen M (2015) Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients. J Affect Disord 174:303–309CrossRef
18.
Kazis DA, Kimiskidis VK, Papagiannopoulos S, Sotirakoglou K, Divanoglou D, Vlaikidis N, Mills KR, Kazis A (2006) The effect of valproate on silent period and corticomotor excitability. Epileptic Disord 8:136–142PubMed
19.
Lee HW, Seo HJ, Cohen LG, Bagic A, Theodore WH (2005) Cortical excitability during prolonged antiepileptic drug treatment and drug withdrawal. Clin Neurophysiol 116:1105–1112CrossRef
20.
Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, di Lazzaro V, Filipovic SR, Grefkes C, Hasan A, Hummel FC, Jaaskelainen SK, Langguth B, Leocani L, Londero A, Nardone R, Nguyen JP, Nyffeler T, Oliveira-Maia AJ, Oliviero A, Padberg F, Palm U, Paulus W, Poulet E, Quartarone A, Rachid F, Rektorova I, Rossi S, Sahlsten H, Schecklmann M, Szekely D, Ziemann U (2020) Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clin Neurophysiol 131:474–528CrossRef
21.
22.
Li X, Ricci R, Large CH, Anderson B, Nahas Z, George MS (2009) Lamotrigine and valproic acid have different effects on motorcortical neuronal excitability. J Neural Transm (Vienna) 116:423–429CrossRef
23.
Malhi GS, Tanious M, Das P, Coulston CM, Berk M (2013) Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 27:135–153CrossRef
24.
McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, Cook IA, O’Reardon J, Husain MM, Wall C, Krystal AD, Sampson SM, Morales O, Nelson BG, Latoussakis V, George MS, Lisanby SH, National network of depression centers R, T. M. S. T. G., American psychiatric association council on research task force on novel, B. & Treatments (2018) Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. J Clin Psychiatry 79:35–48CrossRef
25.
Minzenberg MJ, Leuchter AF (2019) The effect of psychotropic drugs on cortical excitability and plasticity measured with transcranial magnetic stimulation: Implications for psychiatric treatment. J Affect Disord 253:126–140CrossRef
26.
O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA (2007) Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 62:1208–1216CrossRef
27.
Premoli I, Castellanos N, Rivolta D, Belardinelli P, Bajo R, Zipser C, Espenhahn S, Heidegger T, Muller-Dahlhaus F, Ziemann U (2014) TMS-EEG signatures of GABAergic neurotransmission in the human cortex. J Neurosci 34:5603–5612CrossRef
28.
Rossi S, Hallett M, Rossini PM, Pascual-Leone A, SAFETY OF, T. M. S. C. G. (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120:2008–2039CrossRef
29.
Schloesser RJ, Martinowich K, Manji HK (2012) Mood-stabilizing drugs: mechanisms of action. Trends Neurosci 35:36–46CrossRef
30.
Schulze L, Remington G, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J (2017) Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression. J Psychopharmacol 31:312–319CrossRef
31.
Shine B, McKnight RF, Leaver L, Geddes JR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386:461–468CrossRef
32.
Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, Reis C, Normann C, Anghelescu IG, Correll CU (2016) Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr 21:403–418CrossRef
33.
Strigaro G, Varrasi C, Cantello R (2011) Re: modulation of human motor cortex excitability by valproate. Psychopharmacology 216:145–146CrossRef
34.
Tondo L, Alda M, Bauer M, Bergink V, Grof P, Hajek T, Lewitka U, Licht RW, Manchia M, Muller-Oerlinghausen B, Nielsen RE, Selo M, Simhandl C, Baldessarini RJ, International group for studies of L (2019) Clinical use of lithium salts: guide for users and prescribers. Int J Bipolar Disord 7:16CrossRef
35.
Verduijn J, Verhoeven JE, Milaneschi Y, Schoevers RA, van Hemert AM, Beekman ATF, Penninx B (2017) Reconsidering the prognosis of major depressive disorder across diagnostic boundaries: full recovery is the exception rather than the rule. BMC Med 15:215CrossRef
36.
Voytovych H, Krivanekova L, Ziemann U (2012) Lithium: a switch from LTD- to LTP-like plasticity in human cortex. Neuropharmacology 63:274–279CrossRef
37.
Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W (1996) Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 40:367–378CrossRef
38.
Zunhammer M, Langguth B, Landgrebe M, Frank E, Muller S, Burger J, Sand PG, Eichhammer P, Hajak G (2011) Modulation of human motor cortex excitability by valproate. Psychopharmacology 215:277–280CrossRef
Metadata
Title
Antidepressant effect of repetitive transcranial magnetic stimulation is not impaired by intake of lithium or antiepileptic drugs
Authors
T. Hebel
M. A. Abdelnaim
M. Deppe
P. M. Kreuzer
A. Mohonko
T. B. Poeppl
R. Rupprecht
B. Langguth
M. Schecklmann
Publication date
01-10-2021
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2021
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-021-01287-3

Other articles of this Issue 7/2021

European Archives of Psychiatry and Clinical Neuroscience 7/2021 Go to the issue

Correction

Correction to: Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial

Original Paper

Increased subcortical region volume induced by electroconvulsive therapy in patients with schizophrenia

Original Paper

Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders

Editorial

Improvement in daily functioning after aerobic exercise training in schizophrenia is sustained after exercise cessation

Correction

Correction to: Current clinical practice of electroconvulsive therapy and repetitive transcranial magnetic stimulation in psychiatry, a German sample

Original Paper

A symptom-based approach in predicting ECT outcome in depressed patients employing MADRS single items